The drug is now in Phase III of clinical trials. PLN-74809, the leading program from Pliant Therapeutics, is an oral, small-molecule dual selective inhibitor targeting αVβ1 and αVβ6 integrins, under development for idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC)...
Erythropoietin (EPO) has been used extensively in the past by the athletic community in this role. Its main disadvantages are the side effects due to increased viscosity, and the recent development of a blood test for drug testing methods. Two new methods of increasing red blood cell ...
I. pharmacology, clinical history, administration, side effects, and safety. Ritodrine hydrochloride has become the first drug approved in the United States specifically for use in preterm labor. The drug is a beta-sympathomimetic agent with predominant effects upon beta 2 receptors of the uterus. ...
Drug interactionsmay change how yourmedicationswork or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor...
As this dose of epoprostenol could be tolerated readily, epoprostenol therapy could prove a therapeutic advance in some liver disorders, particularly liver transplantation, and possibly in the therapy of certain drug overdoses. 展开 DOI: 10.1016/0262-1746(83)90057-4 ...
In this article, we consider the evidence supporting EPO as a general tissue protective drug and discuss the poten- tial mechanisms by which it may achieve this general effect. We then focus on the renal protective effects of EPO and the potential mechanisms through which it may confer this ...
[KEY WORDS]lymphoma, large B-cell, diffuse; drug therapy; treatment outcome; drug-related side effects and adverse reactions 彌漫大B细胞淋巴瘤(DLBCL)是最常见的非霍奇金淋巴瘤,占全部非霍奇金淋巴瘤的35%～40%,其临床表现和预后等具有高度的异质性。双表达淋巴瘤(DEL)是指Myc蛋白和B细胞淋巴瘤因子(Bcl...
应用^3H-TdR掺入法,动态观察了20例急性早幼粒细胞白血病(APL)患者在应用全反式维甲酸(ATRA)诱导治疗过程中血清Epo的水平。结果表明治疗达骨髓缓解时较治疗前血清Epo含量显著降低(P<0.001),但与正常值无明显差异,与此同时Hb含量上升(P<0.025),随治疗骨髓L-CFU逐渐下降,并与病情同步变化。相关分析表明Epo含量与Hb...
[KEY WORDS]lymphoma,large B-cell,diffuse; drug therapy; treatment outcome; drug-related side effects and adverse reactions 弥漫大B细胞淋巴瘤(DLBCL)是最常见的非霍奇金淋巴瘤,占全部非霍奇金淋巴瘤的35%～40%,其临床表现和预后等具有高度的异质性。双表达淋巴瘤(DEL)是指Myc蛋白和B细胞淋巴瘤因子(Bcl)...
A more recent pharmaceutical drug those athletes are trying would be Erythropoietin, or EPO. According to an entry in the Encyclopædia Britannica, EPO works by “increasing or decreasing the rate of red cell production in accordance with need.” Athletes are taking this hormone by injecting ...